CCM
RXRX icon

CAAS Capital Management’s Recursion Pharmaceuticals RXRX Stock Holding History

CAAS Capital Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-15,000
Closed -$548K – 1089
2021
Q2 		$548K Buy
+15,000
New +$444K 0.01% 712

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CAAS Capital Management's RXRX Position: Q3 2021 in Review

CAAS Capital Management sold out of Recursion Pharmaceuticals (RXRX) in Q3 2021, closing a stake of 15,000 shares — an estimated $548K sold.

CAAS Capital Management first reported a position in RXRX in Q2 2021 and held it in 1 quarter. The position peaked at $548K in Q2 2021. 84 funds tracked by Wall St. Rank hold RXRX as of Q3 2021.

  • CAAS Capital Management reported no remaining Recursion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • CAAS Capital Management sold 15,000 Recursion Pharmaceuticals shares in Q3 2021, an estimated $548K.
  • CAAS Capital Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • CAAS Capital Management's Recursion Pharmaceuticals position peaked at $548K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2021.

Based on CAAS Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.